Melinta Therapeutics, Inc. reported consolidated earnings results for the second quarter ended June 30, 2018. Total revenue was $12,022,000 compared to $3,978,000 a year ago. Loss from operations was $49,726,000 compared to $17,793,000 a year ago. Net loss was $55,780,000 compared to $20,425,000 a year ago. Net loss available to common shareholders was $55,780,000 compared to $26,146,000 a year ago. Basic and diluted net loss per share was $1.38 compared to $884.06 a year ago. Net cash used in operating activities was $54,331,000 compared to $16,500,000 a year ago. Purchases of intangible assets was $2,000,000 compared to $3,500,000 a year ago. Purchases of property, plant and equipment was $423,000 compared to $484,000 a year ago. LBITDA was $38,370,000 compared to $18,540,000 a year ago. Adjusted LBITDA was $36,078,000 compared to $17,114,000 a year ago.

The company expect sales trajectory to increase in the second half of the year, powered by significantly increased presence in the marketplace and expanded and now fully cross-trained sales force of 170 highly experienced sales representatives, with average hospital expertise of 15 years.